Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Escitalopram Pretreatment on Psilocybin Response
NCT03912974Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Jul 2019
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (2 arms), sponsored by University Hospital Basel. Primary endpoint: 5 Dimensions of Altered State of Consciousness Profile Total Score at Day 14. Started Jul 2019; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03912974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912974.